Alvaro Herrera Pérez/LinkedIn
Jun 13, 2026, 16:21
Alvaro Herrera Pérez: Connecting Science and Care at EHA 2026
Alvaro Herrera Pérez, European MSL Lead at Agios Pharmaceuticals, shared a post on LinkedIn:
”Attending EHA 2026 at Stockholm.
Different country, same mission: collaborating with colleagues across Europe and the United States (Clinical Development and Medical Affairs) united by a common purpose: Improving outcomes for patients.
Scientific exchange, innovation, and teamwork continue to drive us forward, always with the patient at the center of everything we do.”
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 10:32Ibrahim Gwarzo: Identifying Care Gaps and Emergency Pain Delays in Sickle Cell Disease at APHA 2026
-
Nov 15, 2026, 10:17Ify Osunkwo: How the Sickle Cell Community Can Influence FDA Drug Development Priorities
-
Nov 15, 2026, 10:11Ahmed Abdelsalam: Why Matching ABO and RhD Groups Does Not Guarantee Crossmatch Compatibility
-
Nov 15, 2026, 10:06Asma Khalil: New British Society for Haematology Guidance on Paediatric and Neonatal Transfusion
-
Nov 15, 2026, 09:41Girishkumar Modi: Navigating the 2026 Jehovah’s Witness Transfusion Policy Shift in Clinical Practice
-
Nov 15, 2026, 04:31Aakriti Gupta: Anticoagulation for Leaflet Thickening After TAVR
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis